JLE

Hépato-Gastro & Oncologie Digestive

MENU

Toxicité hépatique des inhibiteurs des tyrosines kinases en cancérologie Volume 25, numéro 5, Mai 2018

  • [1] Tiemsani C, Huillard O, Arrondeau J, et al. Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors : consequences for the clinical management of sorafenib and regorafenib. Expert Opin Drug MetabToxicol 2015 ; 11 : 785-94.
  • [2] Teo YL, Ho HK, Chan A. Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients : A meta-analysis. Cancer Treat Rev 2013 ; 39 : 199-206.
  • [3] Iacovelli R, Palazzo A, Procopio G, et al. Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. Br J Clin Pharmacol 2013 ; 77 : 929-38.
  • [4] Klümpen H.J., Samer C.F., Mathijssen R.H. Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treat Rev. 2011;37:251-260.
  • [5] Yu K., Geng X., Chen M. High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury. Drug Metab Dispos. 2014;42:744-750.
  • [6] Xu C., Xue Z., Bing N. Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer. Ann Oncol. 2012;23:2470-2471.
  • [7] Boudou-Rouquette P, Narjoz C, Golmard JL, et al. Early sorafenib-induced toxicity is associated with drug exposure and UGT1A9 genetic polymorphism in patients with solid tumors: A preliminary study. PLoS One 2012 ; 7 : e42875.
  • [8] Terada T., Noda S., Inui K. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors. Pharmacol Ther. 2015;152:125-134.
  • [9] Teo YL, Ho, HK, Chan A. Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: A literature review. Expert Opin Drug Metab Toxicol 2015 ; 11 : 231-42.
  • [10] Li X., Kamanacka T.M., Cameron D. Bioactivation of the epidermal growth factor receptor inhibitor gefitinib : implications for pulmonary and hepatic toxicities. Chem Res Toxicol. 2009;22:1736-1742.
  • [11] Chan E.C., New L.S., Chua T.B. Interaction of lapatinib with cytochrome P450 3A5. Drug Metab Dispos. 2012;40:1414-1422.
  • [12] Hardy K.D., Wahlin M.D., Papageorgiou I. Studies on the role of metabolic activation in tyrosine kinase inhibitor-dependant hepatotoxicity : induction of CYP3A4 enhances the cytotoxicity of lapatinib in HepaRG cells. Drug Metab Dispos. 2014;42:162-171.
  • [13] Spraggs CF, Xu CF, Hunt CM. Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors. Pharmacogenomics 2013 ; 14 : 541-54.
  • [14] Spraggs C.F., Budde L.R., Briley L.P. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol. 2011;29:667-673.
  • [15] Krishnamoorthy S.K., Relias N., Sebastian S. Management of regorafenib-related toxicities. A review. Ther Adv Gastroenterol. 2015;8:285-297.
  • [16] Goodman V., Wang Q., Pandite L. Incidence and management of hepatic toxicity in pazopanib-treated patients. Ann Oncol. 2011;21:viii282. Suppl. 8
  • [17] Reuben A. Hy's law. Hepatology. 2004;39:574-578.
  • [18] Shah R.R., Roberts S.A., Shah D.R. A fresh perspective on comparing the FDA and the CHMP/EMA: Approval of antineoplastic tyrosine kinase inhibitors. Br J Clin Pharmacol. 2013;76:396-411.
  • [19] Mir O, Coriat R, Blanchet B, et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One 2012 ; 7 : e7563.
  • [20] Inhibiteurs de la tyrosine kinase BCR-ABL : Glivec®, Sprycel®, Tasigna®, Bosulif®, Iclusig® – le dépistage du virus de l’hépatite B (VHB) doit être réalisé avant l’initiation du traitement, en raison du risque de réactivation de l’hépatite B. Lettre aux professionnels de santé. Information transmise sous l’autorité de l’ANSM. Avril 2016.
  • [21] Food and Drug Administration. Product reviews and labels. http :/www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed 12 Jan 2013.
  • [22] Seki N., Uematsu K., Shibakuki R. Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration. J Clin Oncol. 2006;24:3213-3214. author reply 14-5
  • [23] Gastrointestinal stromal tumors : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25(Suppl. 3):iii21-6.
  • [24] Kijima T., Shimizu T., Nonen S. Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism. J Clin Oncol. 2011;29:e588-e590.
  • [25] Ferrero D., Pogliani E.M., Rege-Cambrin G. Corticosteroids can reverse severe imatinib-induced hepatotoxicity. Haematologica. 2006;91:ECR27.